Thus, we next evaluated whether the decreases in visceral obesity and NAFLD following fenofibrate treatment in obese OVX mice may have resulted from the stimulatory effect of fenofibrate on the adipose tissue expression of PPARα target genes, which are responsible for fatty acid β-oxidation. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.